Tuesday Apr 8
Stemline Therapeutics Announces FDA Acceptance of IND for SL-701
Stemline Therapeutics, Inc. announced today that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme in first recurrence.
Stemline Therapeutics, Inc. To Present At The 13th Annual Healthcare Conference
Stemline Therapeutics, Inc. announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 12:10 PM ET.
The Motley Fool
Where are They Now? Biotech IPO Class of 2013, March Edition
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year.